NEW YORK (GenomeWeb) – Biocartis today announced it has obtained CE-IVD marking for and commercially launched the Idylla molecular diagnostics platform and BRAF Mutation Test.

Idylla is a fully automated real-time PCR system that allows clinicians to perform molecular testing at any time without the need for batching or for trained personnel. It can produce test results in 35 minutes to two hours, enabling same-day results, and its multiplex capability allows for the detection of up to 30 targets with the same sample, the company said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.

Sponsored by

This webinar will discuss how acoustic liquid handling can reduce the time and costs for labs performing carrier screening with next-generation sequencing.

Sponsored by

This webinar will discuss a new approach to amplicon sequencing that addresses the current inefficiencies of the method, such as small designs, primer drop outs, and low uniformity.

Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

Sponsored by

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.